Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Three Stocks That Could Be Trading Below Their Estimated Intrinsic Value

In This Article:

As global markets continue to experience fluctuations, with U.S. stocks reaching record highs amid optimism for softer tariffs and AI-related investments, investors are increasingly focused on identifying opportunities that may be trading below their intrinsic value. In such a climate, finding stocks that are potentially undervalued can be particularly appealing, as they offer the possibility of capitalizing on market inefficiencies while navigating the evolving economic landscape.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Sichuan Injet Electric (SZSE:300820)

CN¥50.58

CN¥100.77

49.8%

GlobalData (AIM:DATA)

£1.78

£3.56

49.9%

Fudo Tetra (TSE:1813)

¥2192.00

¥4357.83

49.7%

J Trust (TSE:8508)

¥520.00

¥1039.92

50%

Bufab (OM:BUFAB)

SEK464.20

SEK926.28

49.9%

Greenworks (Jiangsu) (SZSE:301260)

CN¥13.83

CN¥27.64

50%

IDP Education (ASX:IEL)

A$13.17

A$26.31

49.9%

Allied Blenders and Distillers (NSEI:ABDL)

₹394.40

₹787.12

49.9%

Condor Energies (TSX:CDR)

CA$1.83

CA$3.64

49.7%

Vista Group International (NZSE:VGL)

NZ$3.24

NZ$6.15

47.3%

Click here to see the full list of 904 stocks from our Undervalued Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Salvatore Ferragamo

Overview: Salvatore Ferragamo S.p.A. is a luxury goods company that designs, produces, and sells products for men and women across Europe, North America, Japan, the Asia Pacific, and Central and South America with a market cap of approximately €1.17 billion.

Operations: The company's revenue primarily comes from its footwear segment, which generated €1.08 billion.

Estimated Discount To Fair Value: 35.3%

Salvatore Ferragamo is trading at €7.28, significantly below its estimated fair value of €11.24, highlighting its undervaluation based on discounted cash flow analysis. Despite recent volatility and a decline in profit margins to 0.9%, earnings are expected to grow substantially at 38.1% annually, surpassing the Italian market's growth rate of 6.7%. However, future return on equity remains low at a forecasted 4.8% in three years.

BIT:SFER Discounted Cash Flow as at Jan 2025
BIT:SFER Discounted Cash Flow as at Jan 2025

Haisco Pharmaceutical Group

Overview: Haisco Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and sale of pharmaceuticals in China with a market cap of CN¥35.37 billion.

Operations: The company's revenue is primarily derived from its activities in researching, developing, manufacturing, and selling pharmaceuticals within China.